[Comment] Long-term efficacy of ibrutinib–venetoclax for first-line treatment in chronic lymphocytic leukaemia

The results of the primary endpoint of the GLOW study1 formed the basis for approval of ibrutinib (a BTK inhibitor) and venetoclax (a BCL-2 inhibitor) combination therapy for first-line treatment of chronic lymphocytic leukaemia. This approach is now integrated in clinical practice. However, the analysis of long-term data by Carsten U Niemann and colleagues,2 after a median observation time of nearly 4 years, can address several key questions that have arisen in the context of this therapy.